BACKGROUND Very little is known about the role of extracorporeal membrane oxygenation(ECMO)for the management of patients undergoing major aortic surgery with particular reference to aortic dissection.AIM To review th...BACKGROUND Very little is known about the role of extracorporeal membrane oxygenation(ECMO)for the management of patients undergoing major aortic surgery with particular reference to aortic dissection.AIM To review the available literature to determine if there was any evidence.METHODS A systematic literature search through PubMed and EMBASE was undertaken according to specific key words.RESULTS The search resulted in 29 publications relevant to the subject:1 brief communication,1 surgical technique report,1 invited commentary,1 retrospective case review,1 observational study,4 retrospective reviews,13 case reports and 7 conference abstracts.A total of 194 patients were included in these publications of whom 77 survived.CONCLUSION Although there is no compelling evidence for or against the use of ECMO in major aortic surgery or dissection,it is enough to justify its use in this patient population despite current adverse attitude.展开更多
Background Extra-corporeal membranous oxygenation (ECMO)and intra-aortic balloon pumping (IABP) are widely used in patients with severe circulatory failure. The decision to initiate ECMO and IABP on optimal occasion i...Background Extra-corporeal membranous oxygenation (ECMO)and intra-aortic balloon pumping (IABP) are widely used in patients with severe circulatory failure. The decision to initiate ECMO and IABP on optimal occasion in postcardiotomy cardiogenic shock (PCS) remains controversial in the absence of guidelines.展开更多
Background:Although the use of extra-corporeal membrane oxygenation (ECMO) has been rapidly increasing,the benefit of ECMO in patients with acute respiratory distress syndrome (ARDS) remains unclear.Our objective was ...Background:Although the use of extra-corporeal membrane oxygenation (ECMO) has been rapidly increasing,the benefit of ECMO in patients with acute respiratory distress syndrome (ARDS) remains unclear.Our objective was to investigate the effect of venovenous ECMO (VV-ECMO) on adult patients with severe ARDS.Methods:We conducted a multi-center,retrospective,cohort study in the intensive care units (ICUs) of six teaching hospitals between January 2013 and December 2018.Patients with severe ARDS who received W-ECMO support were included.The detailed demographic data and physiologic data were used to match ARDS patients without ECMO.The primary endpoint was the 28-day mortality.Results:Ninety-nine patients with severe ARDS supported by VV-ECMO and 72 patients without ECMO were included in this study.The acute physiology and chronic health evaluation Ⅱ score was 23.1 ± 6.3 in the ECMO group and 24.8 ± 8.5 in the control group (P =0.1195).The sequential organ failure assessment score was 12.8 ± 3.4 in the ECMO group and 13.7 ± 3.5 in the control group (P =0.0848).The 28-day mortality of patients with ECMO support was 39.4%,and that of the control group was 55.6%.The survival analysis curve showed that the 28-day mortality in the ECMO group was significantly lower than that in the control group (P =0.0097).Multivariate Cox regression analysis showed that the independent predictors of the 28-day mortality were the requirement of vasopressors before ECMO (hazard ratio [HR]:1.006;95% confidence interval [CI]:1.001-1.013;P =0.030) and duration of mechanical ventilation before ECMO (HR:3.299;95% CI:1.264-8.609;P =0.034).Conclusions:This study showed that ECMO improved the survival of patients with severe ARDS.The duration of mechanical ventilation and the requirement of vasopressors before ECMO might be associated with an increased risk of death.展开更多
新生儿持续性肺动脉高压(persistent pulmonary hypertension of the newborn,PPHN)是指生后肺血管阻力持续性增高,使由胎儿型循环过渡至正常“成人”型循环发生障碍,而引起的心房和(或)动脉导管水平血液的右向左分流,临床出现严重低氧...新生儿持续性肺动脉高压(persistent pulmonary hypertension of the newborn,PPHN)是指生后肺血管阻力持续性增高,使由胎儿型循环过渡至正常“成人”型循环发生障碍,而引起的心房和(或)动脉导管水平血液的右向左分流,临床出现严重低氧血症等症状。新生儿持续性肺动脉高压约占活产新生儿的0.2%[1],但在所有呼吸衰竭新生儿中伴有不同程度的肺动脉高压的比例可高达10%,并有相对较高的死亡率[2]。症状轻的患儿可采用吸入一氧化氮,高频振荡通气进行治疗,吸入一氧化氮可成功改善60%~70%的患儿氧合作用,改善PPHN[3]。对于一氧化氮治疗效果差且患儿饱和度持续不升的患儿,结合临床指标及时应用体外膜肺氧合(extracorporeal membrance oxygenation,ECMO)技术[4]。ECMO是对传统医学疗法难以治疗的严重心血管或呼吸衰竭病人的一种支持疗法[5]。ECMO是将静脉血从体内引流到体外,经模式氧合器氧合后再用血泵将血液灌入体内[6-7]。临床上主要用于呼吸功能不全和心脏功能不全的支持,ECMO在一段时间内替代或部分替代人的心、肺功能,支持生命,以争取心、肺功能的恢复及病变的治愈[8]。研究表明,ECMO的使用有所增加,且持续时间更长,是一种重要的支持疗法,肺功能恢复是终止ECMO的主要指证[9]。2017年7月—2017年8月我科共实施ECMO辅助治疗新生儿持续性肺动脉高压患儿2例,现将护理总结如下。展开更多
目的回顾性研究接受心脏移植手术并采用体外膜氧合(ECMO)辅助支持治疗的患者,总结临床经验,为进一步推广提供参考。方法收集中国医学科学院阜外心血管病医院接受心脏移植手术并采用ECMO支持受者的临床资料,分析受者围手术期ECMO应用情况...目的回顾性研究接受心脏移植手术并采用体外膜氧合(ECMO)辅助支持治疗的患者,总结临床经验,为进一步推广提供参考。方法收集中国医学科学院阜外心血管病医院接受心脏移植手术并采用ECMO支持受者的临床资料,分析受者围手术期ECMO应用情况,统计ECMO支持时间,合并使用主动脉内球囊反搏(IABP)的情况,并发症发生情况等临床资料。采用SPSS23.0软件处理,正态分布采用独立样本Student's test,非正态分布采用非参数检验Mann-Whitney U test。分类资料的组间比较采用χ2检验或Fisher确切检验法。结果所有ECMO支持模式均为静脉-动脉ECMO模式(V-A ECMO)。有8例受者成功使用ECMO过渡到心脏移植。使用ECMO的心脏移植受者中61例(89.7%)成功脱离ECMO机械辅助,48例(70.5%)存活出院。出血、术后急性肾功能不全、肺部感染等并发症是心脏移植ECMO循环支持过程中最多见的并发症。在手术室早期建立ECMO辅助循环的心脏移植受者脱机率和存活率分别为95.6%和84.4%,而在ICU床旁建立ECMO的受者脱机率和存活率分别为72.2%和27.8%,早期使用ECMO结果更好。结论ECMO机械辅助循环能对心脏移植受者提供有效的循环、呼吸功能支持,使得受者平稳渡过移植手术围术期。提倡早期、同期联合应用IABP增加重要器官的灌注,改善受者的预后,获得良好的转归。展开更多
文摘BACKGROUND Very little is known about the role of extracorporeal membrane oxygenation(ECMO)for the management of patients undergoing major aortic surgery with particular reference to aortic dissection.AIM To review the available literature to determine if there was any evidence.METHODS A systematic literature search through PubMed and EMBASE was undertaken according to specific key words.RESULTS The search resulted in 29 publications relevant to the subject:1 brief communication,1 surgical technique report,1 invited commentary,1 retrospective case review,1 observational study,4 retrospective reviews,13 case reports and 7 conference abstracts.A total of 194 patients were included in these publications of whom 77 survived.CONCLUSION Although there is no compelling evidence for or against the use of ECMO in major aortic surgery or dissection,it is enough to justify its use in this patient population despite current adverse attitude.
文摘Background Extra-corporeal membranous oxygenation (ECMO)and intra-aortic balloon pumping (IABP) are widely used in patients with severe circulatory failure. The decision to initiate ECMO and IABP on optimal occasion in postcardiotomy cardiogenic shock (PCS) remains controversial in the absence of guidelines.
基金This work was supported by grants from the Jiangsu Province's Key Discipline/Laboratory of Medicine (No. ZDXKA2016025)the Jiangsu Province's Key Provincial Talents Program (No.ZDRCA2016082)the National Natural Science Foundation of China (No.81370180).
文摘Background:Although the use of extra-corporeal membrane oxygenation (ECMO) has been rapidly increasing,the benefit of ECMO in patients with acute respiratory distress syndrome (ARDS) remains unclear.Our objective was to investigate the effect of venovenous ECMO (VV-ECMO) on adult patients with severe ARDS.Methods:We conducted a multi-center,retrospective,cohort study in the intensive care units (ICUs) of six teaching hospitals between January 2013 and December 2018.Patients with severe ARDS who received W-ECMO support were included.The detailed demographic data and physiologic data were used to match ARDS patients without ECMO.The primary endpoint was the 28-day mortality.Results:Ninety-nine patients with severe ARDS supported by VV-ECMO and 72 patients without ECMO were included in this study.The acute physiology and chronic health evaluation Ⅱ score was 23.1 ± 6.3 in the ECMO group and 24.8 ± 8.5 in the control group (P =0.1195).The sequential organ failure assessment score was 12.8 ± 3.4 in the ECMO group and 13.7 ± 3.5 in the control group (P =0.0848).The 28-day mortality of patients with ECMO support was 39.4%,and that of the control group was 55.6%.The survival analysis curve showed that the 28-day mortality in the ECMO group was significantly lower than that in the control group (P =0.0097).Multivariate Cox regression analysis showed that the independent predictors of the 28-day mortality were the requirement of vasopressors before ECMO (hazard ratio [HR]:1.006;95% confidence interval [CI]:1.001-1.013;P =0.030) and duration of mechanical ventilation before ECMO (HR:3.299;95% CI:1.264-8.609;P =0.034).Conclusions:This study showed that ECMO improved the survival of patients with severe ARDS.The duration of mechanical ventilation and the requirement of vasopressors before ECMO might be associated with an increased risk of death.
文摘新生儿持续性肺动脉高压(persistent pulmonary hypertension of the newborn,PPHN)是指生后肺血管阻力持续性增高,使由胎儿型循环过渡至正常“成人”型循环发生障碍,而引起的心房和(或)动脉导管水平血液的右向左分流,临床出现严重低氧血症等症状。新生儿持续性肺动脉高压约占活产新生儿的0.2%[1],但在所有呼吸衰竭新生儿中伴有不同程度的肺动脉高压的比例可高达10%,并有相对较高的死亡率[2]。症状轻的患儿可采用吸入一氧化氮,高频振荡通气进行治疗,吸入一氧化氮可成功改善60%~70%的患儿氧合作用,改善PPHN[3]。对于一氧化氮治疗效果差且患儿饱和度持续不升的患儿,结合临床指标及时应用体外膜肺氧合(extracorporeal membrance oxygenation,ECMO)技术[4]。ECMO是对传统医学疗法难以治疗的严重心血管或呼吸衰竭病人的一种支持疗法[5]。ECMO是将静脉血从体内引流到体外,经模式氧合器氧合后再用血泵将血液灌入体内[6-7]。临床上主要用于呼吸功能不全和心脏功能不全的支持,ECMO在一段时间内替代或部分替代人的心、肺功能,支持生命,以争取心、肺功能的恢复及病变的治愈[8]。研究表明,ECMO的使用有所增加,且持续时间更长,是一种重要的支持疗法,肺功能恢复是终止ECMO的主要指证[9]。2017年7月—2017年8月我科共实施ECMO辅助治疗新生儿持续性肺动脉高压患儿2例,现将护理总结如下。
文摘目的回顾性研究接受心脏移植手术并采用体外膜氧合(ECMO)辅助支持治疗的患者,总结临床经验,为进一步推广提供参考。方法收集中国医学科学院阜外心血管病医院接受心脏移植手术并采用ECMO支持受者的临床资料,分析受者围手术期ECMO应用情况,统计ECMO支持时间,合并使用主动脉内球囊反搏(IABP)的情况,并发症发生情况等临床资料。采用SPSS23.0软件处理,正态分布采用独立样本Student's test,非正态分布采用非参数检验Mann-Whitney U test。分类资料的组间比较采用χ2检验或Fisher确切检验法。结果所有ECMO支持模式均为静脉-动脉ECMO模式(V-A ECMO)。有8例受者成功使用ECMO过渡到心脏移植。使用ECMO的心脏移植受者中61例(89.7%)成功脱离ECMO机械辅助,48例(70.5%)存活出院。出血、术后急性肾功能不全、肺部感染等并发症是心脏移植ECMO循环支持过程中最多见的并发症。在手术室早期建立ECMO辅助循环的心脏移植受者脱机率和存活率分别为95.6%和84.4%,而在ICU床旁建立ECMO的受者脱机率和存活率分别为72.2%和27.8%,早期使用ECMO结果更好。结论ECMO机械辅助循环能对心脏移植受者提供有效的循环、呼吸功能支持,使得受者平稳渡过移植手术围术期。提倡早期、同期联合应用IABP增加重要器官的灌注,改善受者的预后,获得良好的转归。
